|
| Group A | Group B | p |
| Number of patients | 107 | 55 |
|
| Average Age | 50 | 47 | 0.15 |
| Sex | 60F/47H | 30F/25H | 0.45 |
| Genotype | G1: 76 G2: 31 | G1: 40 G2: 14 G1 et 4: 1 case |
|
| Cirrhosis | 49 | 36 | 0.5 |
| Viral load | 455,233 UI/ML | 400,034 UI/ML | 0.66 |
| Sustained viral response rate | 59% or 55.14% | 54% or 98.18% | p < 0.0001 |
| Failure rate | 14% or 13.1% | 1% or 2% | p = 0.019 |
| Relapse rate | 14% or 13.1% | 0% | p = 0.003 |
| Side effects | Anemia; thrombocytopenia; pancytopenia; diarrhea; vomiting; anorexia; asthenia; sleep disorders; dementia syndrome; seizure disorder; depressive syndrome | Vomiting; nausea Myalgias; asthenia |
|
| Tolerance | 45.7% | 9% | p < 0.001 |